Back to Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

Liposomes and nanotechnology in drug development: focus on ocular targets

Authors Honda M, Asai T, Oku N, Araki Y, Tanaka M, Ebihara N

Received 5 November 2012

Accepted for publication 31 December 2012

Published 14 February 2013 Volume 2013:8(1) Pages 495—504

DOI https://doi.org/10.2147/IJN.S30725

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Miki Honda,1 Tomohiro Asai,2 Naoto Oku,2 Yoshihiko Araki,3 Minoru Tanaka,1 Nobuyuki Ebihara1

1Department of Ophthalmology, Juntendo University Urayasu Hospital, Chiba, Japan; 2Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan; 3Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan

Abstract: Poor drug delivery to lesions in patients' eyes is a major obstacle to the treatment of ocular diseases. The accessibility of these areas to drugs is highly restricted by the presence of barriers, including the corneal barrier, aqueous barrier, and the inner and outer blood–retinal barriers. In particular, the posterior segment is difficult to reach for drugs because of its structural peculiarities. This review discusses various barriers to drug delivery and provides comprehensive information for designing nanoparticle-mediated drug delivery systems for the treatment of ocular diseases. Nanoparticles can be designed to improve penetration, controlled release, and drug targeting. As highlighted in this review, the therapeutic efficacy of drugs in ocular diseases has been reported to be enhanced by the use of nanoparticles such as liposomes, micro/nanospheres, microemulsions, and dendrimers. Our recent data show that intravitreal injection of targeted liposomes encapsulating an angiogenesis inhibitor caused significantly greater suppression of choroidal neovascularization than did the injection of free drug. Recent progress in ocular drug delivery systems research has provided new insights into drug development, and the use of nanoparticles for drug delivery is thus a promising approach for advanced therapy of ocular diseases.

Keywords: intravitreal injection, drug delivery system, age-related macular degeneration, APRPG-modified PEGylated liposome, DDS

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]